Literature DB >> 16081780

Activation of V gamma 9V delta 2 T cells by NKG2D.

Bladimiro Rincon-Orozco1, Volker Kunzmann, Philine Wrobel, Dieter Kabelitz, Alexander Steinle, Thomas Herrmann.   

Abstract

Human Vgamma9 Vdelta2 T cells recognize phosphorylated nonpeptide Ags (so called phosphoantigens), certain tumor cells, and cells treated with aminobisphosphonates. NKG2D, an activating receptor for NK cells, has been described as a potent costimulatory receptor in the Ag-specific activation of gammadelta and CD8 T cells. This study provides evidence that Vgamma9 Vdelta2 T cells may also be directly activated by NKG2D. Culture of PBMC with immobilized NKG2D-specific mAb or NKG2D ligand MHC class I related protein A (MICA) induces the up-regulation of CD69 and CD25 in NK and Vgamma9 Vdelta2 but not in CD8 T cells. Furthermore, NKG2D triggers the production of TNF-alpha but not of IFN-gamma, as well as the release of cytolytic granules by Vgamma9 Vdelta2 T cells. Purified Vgamma9 Vdelta2 T cells kill MICA-transfected RMA mouse cells but not control cells. Finally, DAP10, which mediates NKG2D signaling in human NK cells, was detected in resting and activated Vgamma9 Vdelta2 T cells. These remarkable similarities in NKG2D function in NK and Vgamma9 Vdelta2 T cells may open new perspectives for Vgamma9 Vdelta2 T cell-based immunotherapy, e.g., by Ag-independent killing of NKG2D ligand-expressing tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16081780     DOI: 10.4049/jimmunol.175.4.2144

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  122 in total

1.  An NKG2D-mediated human lymphoid stress surveillance response with high interindividual variation.

Authors:  Seema Shafi; Pierre Vantourout; Graham Wallace; Ayman Antoun; Robert Vaughan; Miles Stanford; Adrian Hayday
Journal:  Sci Transl Med       Date:  2011-11-30       Impact factor: 17.956

Review 2.  Gammadelta T cell effector functions: a blend of innate programming and acquired plasticity.

Authors:  Marc Bonneville; Rebecca L O'Brien; Willi K Born
Journal:  Nat Rev Immunol       Date:  2010-06-11       Impact factor: 53.106

Review 3.  Prospects for chimeric antigen receptor (CAR) γδ T cells: A potential game changer for adoptive T cell cancer immunotherapy.

Authors:  Hamid Reza Mirzaei; Hamed Mirzaei; Sang Yun Lee; Jamshid Hadjati; Brian G Till
Journal:  Cancer Lett       Date:  2016-07-05       Impact factor: 8.679

4.  Isopentenyl pyrophosphate-activated CD56+ {gamma}{delta} T lymphocytes display potent antitumor activity toward human squamous cell carcinoma.

Authors:  Alan A Z Alexander; Amudhan Maniar; Jean-Saville Cummings; Andrew M Hebbeler; Dan H Schulze; Brian R Gastman; C David Pauza; Scott E Strome; Andrei I Chapoval
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 5.  Searching for "signal 2": costimulation requirements of γδ T cells.

Authors:  Julie C Ribot; Ana debarros; Bruno Silva-Santos
Journal:  Cell Mol Life Sci       Date:  2011-05-04       Impact factor: 9.261

6.  BTN3A1 Discriminates γδ T Cell Phosphoantigens from Nonantigenic Small Molecules via a Conformational Sensor in Its B30.2 Domain.

Authors:  Mahboob Salim; Timothy J Knowles; Alfie T Baker; Martin S Davey; Mark Jeeves; Pooja Sridhar; John Wilkie; Carrie R Willcox; Hachemi Kadri; Taher E Taher; Pierre Vantourout; Adrian Hayday; Youcef Mehellou; Fiyaz Mohammed; Benjamin E Willcox
Journal:  ACS Chem Biol       Date:  2017-09-14       Impact factor: 5.100

7.  Low dose gemcitabine increases the cytotoxicity of human Vγ9Vδ2 T cells in bladder cancer cells in vitro and in an orthotopic xenograft model.

Authors:  Teruki Shimizu; Mako Tomogane; Masatsugu Miyashita; Osamu Ukimura; Eishi Ashihara
Journal:  Oncoimmunology       Date:  2018-02-08       Impact factor: 8.110

8.  Correlation of serum MMP3 and other biomarkers with clinical outcomes in patients with ankylosing spondylitis: a pilot study.

Authors:  Dongyi He; Qi Zhu; Quan Zhou; Qing Qi; Hongmei Sun; Liza M Zachariah; Grace Wang; John D Reveille; Yongtao Guan; Xiaodong Zhou
Journal:  Clin Rheumatol       Date:  2017-04-22       Impact factor: 2.980

9.  Control of CD56 expression and tumor cell cytotoxicity in human Vgamma2Vdelta2 T cells.

Authors:  Elizabeth M Urban; Haishan Li; Cheryl Armstrong; Chiara Focaccetti; Cristiana Cairo; C David Pauza
Journal:  BMC Immunol       Date:  2009-09-21       Impact factor: 3.615

10.  Association of MICA-TM and MICB C1_2_A microsatellite polymorphisms with tumor progression in patients with colorectal cancer.

Authors:  R Kopp; J Glas; U Lau-Werner; E D Albert; E H Weiss
Journal:  J Clin Immunol       Date:  2009-04-08       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.